MiR-1-3p • SFRP1 • bladder cancer Abstract Background: Bladder cancer is of compelling morbidity and mortality due to its high recurrence rate. Little development has been made in the last decades in the therapy methods. Thus, the mechanism of its growth and invasiveness involving novel molecular targets are needed. Objective: Our research objective is to confirm the hypothesis that miR-1-3p suppresses the proliferation, invasion and migration of bladder cancer cells. Methods: The expression levels of miR-1-3p and SFRP1 were evaluated using RT-qPCR in bladder cancer tissues and cells as well as in normal tissues and cells. J82 cell lines were selected as experiment subjects due to their low expression levels of miR-1-3p. Plasmids carrying miR-1-3p mimics, miR-1-3p inhibitors and SFRP1 were transfected into the J82 cell lines. Subsequently, the protein expression of SFRP1 was detected using Western Blot analysis, and cell proliferation, apoptosis, invasion and migration ability was measured using MTT, the flow cytometry, the Transwell test and wound healing assays, respectively. Results: Bladder cancer tissues and cells exhibited significant decrease in the expression of miR-1-3p and SFRP1 compared to normal tissues and cells, and human bladder cancer cell line J82 exhibited the most significant decrease in these expressions (P < 0.05). MiR-1-3p up-regulates SFRP1 expression in bladder cancer cells, and the over-expression of miR-1-3p can suppress the proliferation, invasion and migration ability of bladder cancer cells. This mechanism is similar to the effect of SFRP1 over-expression on bladder cancer cells. Conclusion: MiR-1-3p suppresses the proliferation, invasion and migration of bladder cancer cells by up-regulating SFRP1 expression.
Introduction
Bladder cancer, a typical malignant urogenital tract cancer, has become the sixth most common form of cancer and one primary cause of cancer related deaths [1] . About 300,000 new bladder cancer cases are discovered each year around the world [1] . Bladder cancer can be divided into two groups, muscle-invasive bladder cancer and non-muscle-invasive bladder cancer [2] . The recurrence rate of bladder cancer in patients with non-muscle-invasive tumors is high (about 50%) and approximately 15% of these non-muscle-invasive tumors patients develop muscle-invasive tumors [3] . The etiology of bladder cancer includes both environmental and genetic factors [4] . Chemotherapy has been used to treat bladder cancer but it only provides limited benefits [5] . Recent studies found that the down-regulation of certain tumor suppressor genes may trigger the progression of bladder cancer [6] . Therefore, potential gene therapies should be developed to target these tumor suppressor genes [7] .
MicroRNAs (miRNAs) are a group of non-coding RNA molecules of about 20-22 nucleotides in length and they are negative regulators of gene expressions at the posttranscriptional levels [8] . MiRNAs were initially considered as post-transcriptional regulators that controlled cell proliferation, metabolism, differentiation and apoptosis [9] . Also, miRNAs have been reported to act as tumor suppressors or oncogenes [10] . Hence, MiRNAs expression profile analysis may be able to identify critical tumorigenic pathways and predict the prognosis of cancer patients [10] . Moreover, it has been reported that the expression profile of miRNAs is different between normal cells and bladder cancer cells [11] . Different miRNAs can function as either tumor suppressors or activators since they regulate different targets [8] . Several miRNAs have been linked to bladder cancer. For instance, miR-1, miR-133a, and miR-218 may function as tumor suppressive miRNAs since they regulate the LIM and SH3 Protein 1 gene in bladder cancer [12] . MiR-1 has been identified as a tumor suppressor because down-regulations of miRNA have been discovered in bladder cancer [13] . A previous study reported that miR-1 regulates oncogenic transgelin 2 genes in human bladder cancer [13] and that miR-1 also induces the apoptosis of bladder cancer cells by inhibiting the splicing factor serine/arginine-rich 9 [14] . However, the role of miR-1-3p in bladder cancer progression still remains uninvestigated.
Secreted frizzled-related protein 1 (SFRP1) is located in chromosome 8p12-11.1 and acts as an inhibitor of Wnt signaling [15] . SFRP1 has also been identified as a tumor-suppressor gene, whose expression is reduced in various malignancies including colorectal, breast and kidney cancer [15, 16] . For example, SFRP1 was reduced by 38% on average in patients with bladder cancer [15] , and miRNAs are potential regulators of SFRP1. Wu et al. demonstrated that miR-1207 can enhance the stem cell like traits of cancer cells through down-regulating SFRP1 in ovarian cancer [17] . In non-small cell lung carcinoma, the over-expression of miR-582-3p targets SFRP1 [18] . Studies have also indicated that SFRP1 is a direct target gene of both miR-27a and miR-127-3p [16, 19] . In addition, Yang et al. discovered that SFRP1 is likely to affect skeletal muscle development and is regulated by miR-1/206 [20] . As a result, we proposed the hypothesis that miR-1-3p regulates SFRP1, which exhibits a carcinostatic role in bladder cancer.
In the present study, we studied the expression patterns of miR-1-3p and SFRP1 in both bladder cancer cell line and tissues. Finally, the corresponding effects of miR-1-3p and SFRP1 on the proliferation, invasion, and migration of the J82 bladder cancer cell line were examined.
Material and Methods

Cell lines and clinical samples
Clinical samples were collected from 34 patients who received surgical treatment in the Sixth People's Hospital of Yancheng City from March 2015 to October 2015. The pathological characteristics of these patients were shown in Table 1 . Normal tissue samples were obtained 2cm from the edge of the lesion. 
Cellular Physiology and Biochemistry
These samples were placed in liquid nitrogen tanks immediately after collection. Normal bladder epithelium cell line SV-HUC-1 and bladder cancer cell lines (5637, T24, J82 and UM-UC-3) were purchased from the Institute of Biochemistry and Cell Biology and the Chinese Academy of Sciences. All cells were cultured in a RPMI-1640 medium supplemented with 10% fetal-bovine serum in a 37℃, 5% carbon dioxide incubator.
RT-qPCR
Total RNA was extracted from 50 mg frozen tissue samples using the reagent TRIzol. The first-strand cDNA was synthesized and amplified via reverse transcription using PrimeScript RT reagent Kit with gDNA Eraser (TAKARA, Dalian, China, RR047B). Then RT-PCRs were performed with the corresponding specific PrimeScript RT-PCR Kit (TAKARA, Dalian, China, RR014B) for three times in the 7500 PCR system (Applied Biosystems, US). SnRNA U6 and GAPDH mRNA were used as internal controls in the amplification of miR-1-3p and SFRP1. Real-time quantitative data was processed using the 2-DDC t method. The PCR primer sequences are shown in Table 2 .
Cell transfection
The blank plasmid, miR-1-3p mimics and its inhibitors were purchased from GenePharma (Shanghai, China). Cells were digested with trypsin and then seeded onto six-well plates. The transfection was carried out using Lipofectamine 2000 (Invitrogen, MA, USA) and the FuGene HD transfection reagent (Promega, Madison, WI, USA) in accordance with the corresponding manufacturers' instructions. The miR-1-3p mimics and its inhibitors were used at a final concentration of 100 nM, and 4 μg of the pCMV6-Neo control and pCMV6-SFRP-1 plasmids were used. After 24 hours of incubation, the transfected cells were collected 
Western Blotting
After 48hrs of cell incubation, total proteins were extracted by RIPA buffer (Pierce, Rockford, IL, USA, #89900) with the corresponding Protease Inhibitor Cocktail (Pierce, Rockford, IL, USA, #78429). The extracted protein was separated using sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) and transfected to polyvinylidene fluoride (PVDF) membranes. The membranes were blocked in Tris Buffered Saline Tween (TBST) with low fat milk and then incubated overnight with primary antibodies against SFRP1 (1:1000, Abcam, Cambridge, MA, USA, ab4193) and GAPDH (1:800, Santa Cruz, CA ,USA, sc-367715) at 4℃. The membranes were then washed with TBST and incubated with Horseradish peroxidaseconjugated secondary antibody goat anti-rabbit IgG (1:200, Santa Cruz, USA, sc-3836). Finally, the membranes were visualized using ECL developing liquid (Millipore, MA, USA). During this process GAPDH was used as an internal control.
MTT assay J82 cells were seeded in a 96-well plate 24hrs after the transfection. After incubation was carried out for 24hrs, 48hrs, 72hrs and 96hrs, 10μL of 5 mg/mL MTT (Sigma-Aldrich, St. Louis, MO, USA, M2128) solution was added in to cells. After another 4hrs of incubation, the corresponding medium was removed and DMSO (Sigma-Aldrich, St. Louis, MO, USA, D2650) was added. The absorbance at 490 nm was then detected using a spectrophotometer.
Cell cycle assay and apoptosis assay
Cell cycle and apoptosis was analyzed using a flow cytometer. For the cell cycle assay, all the transfected cells were harvested in the log phase of growth, washed with ice-cold PBS buffer and fixed with 70% ethanol for more than 12hrs at 4℃. Subsequently, the fixing buffer was removed, cells were washed, propidium iodide (PI) (BD Pharmingen, San Diego, CA, USA, #556463) buffer was added into cells which were subject to incubated for 30mins at 37℃ in darkness. For the apoptosis assay, cells were collected and re-suspended with a binding buffer 48hrs after the transfection. Annexin V-FITC reagent (BD Pharmingen, San Diego, CA, USA, #550911) was added and mixed with the cells. PI buffer was then added into cells which were incubated in darkness for another 1h at room temperature.
Transwell assay
After transfection had been carried out for 36 hours, cells were digested with trypsin, re-suspended in a serum-free DMEM medium (Invitrogen, Carlsbad, CA, USA, #12491-015) and plated into the matrigel coated Transwell chambers ( Corning, NY, USA, #354168). Chambers were inserted into 12-well plates filled with DMEM +10% FBS. After 24hrs of incubation which was conducted at the temperature of 37℃, the corresponding medium was removed and cells on the upper side of the chamber were cleaned using a cotton swab. Invaded cells were then fixed on a filter using a 4% paraformaldehyde solution. After 15mins, cells were dyed with crystal violet and photographed using a microscope. The number of invaded cells in a five 200× microscopic field was counted and used as the assessment criteria for cell invasion ability.
Wound healing assay
The suspension of cells was seeded into a matrigel coated 96-well plate (BD Bioscience, USA) after 36-hour transfection. Cells were incubated in 1640 medium (10% FBS) until monolayers were developed. An artificial wound was uniformly made in the cell monolayer using a pipette tip. Cells were then washed with a serum-free medium and 1640 medium containing 1% FBS was added into cells. The relative distance of the wound was measured with a microscope after 36hrs of incubation.
Statistical analysis
Statistical analysis was performed using SPSS 22.0. All the experiments were performed in independent biological triplicates and the results were represented as mean ± standard deviation. Comparison between two groups was analyzed using the Student's t-test and one-way ANOVA was utilized for multiple comparisons. Significant difference was suggested if the corresponding P-value for a statistical test is less than 0.05.
Results
Expression levels of miR-1-3p and SFRP1 decreased in bladder cancer tissues and cells
RT-qPCR was used to detect the miR-1-3p and SFRP1 mRNA expression levels. As shown in Figure 1a and 1b, expressions of both miR-1-3p and SFRP1 in bladder cancer tissues were lower than those of normal tissues (P < 0.05). Furthermore, miR-1-3p and SFRP1 expression in bladder cancer cells were lower than those in SV-HUC-1 cells (P < 0.05, shown in Fig. 1c 
MiR-1-3p blocks bladder cancer cell cycle
As illustrated in Figure 2c and 2d, a higher proportion of cells in the miR-mimics and plenti-SFRP1 group stayed in the G0/G1 stage (P < 0.05). The miR-IN group contained more cells which were at the stage of S and G2 compared to the Control-1 group (P < 0.05). No such significant difference was observed when comparing the Mix and Control-2 groups (P > 0.05).
MiR-1-3p stimulates bladder cancer cell apoptosis
As indicated in Figure 2e and 2f, the apoptosis rate in the miR-mimics and plenti-SFRP1 groups were increased significantly compared to that in the Control-1 group (P < 0.05). The miR-IN group exhibited a lower apoptosis rate than that of the Control-1 group (P < 0.05). Cell apoptosis was not significantly different (P > 0.05) between the Mix and Control-2 group. These results indicate that miR-1-3p up-regulates SFRP1 and thereby stimulating cell apoptosis.
MiR-1-3p inhibits bladder cancer cell invasion
As indicated by the Transwell assay ( Fig. 3a and 3b) , the miR-mimics and plenti-SFRP1 group exhibited fewer cells that were penetrated to the matrigel compared to the Control-1 group (P < 0.05). This indicates that J82 cells have a lower invasive ability. Cell invasion ability in the miR IN group was stronger than that of the Control-1 group (P < 0.05). No such significant difference was found between the Mix and Control-2 group (P > 0.05). We hypothesized that miR-1-3p up-regulates SFRP1 expression and inhibits the invasion ability of J82 cells.
MiR-1-3p inhibits bladder cancer cell migration
The wound healing assay (Fig. 3c and 3d ) demonstrated a weaker migration ability of cells in the miR-mimics and plenti-SFRP1 group. This trend is due to the fact that the wound in these groups did not show substantial recovery or narrowing compared to the blank control, negative control, miR-IN and Mix groups. Thus, we concluded that SFRP1 expression and the overexpression of miR-1-3p can reduce cell migration.
Discussion
In our research, the expression of miR-1-3p was substantially lower in cancerous tissues and cells compared to those in normal tissues cells. Other study have also suggested that miR-1-3p and down-regulated significantly in bladder cancer tissues [13] .In addition, our findings indicated that miR-1-3p functions as tumor suppressors in bladder cancer for its effects on the inhibition of proliferation, invasion and migration and the promotion of cell apoptosis. Similarly, Nasser et al. reported that miR-1 played a role as a tumor-suppressed miRNA [21, 22] .
Recent literature has demonstrated that SFRP1 is a cancer suppressor gene in hepatocellular carcinoma [23, 24] . Furthermore, prior studies have also investigated how SFRP1 deficiency is linked with malignancies, including kidney cancer, colorectal cancer and breast cancer [25] [26] [27] . In our study, the SFRP1 mRNA and protein expression levels were significantly lower in bladder cancer tissues and cells compared to those in non-cancerous tissues and normal cells, which is consistent with the study of Buim [28] . During the G2/M phase of the vector transfection of SFRP1 overexpression in J82 cells, the proliferation, invasion, and migration rates decreased significantly whereas the number of cell apoptosis substantially increased. These results further indicate that SFRP1 plays an important role in the suppression of bladder cancer development. Rogler et al. conclusively revealed that SFRP1 loss may be associated with a poor overall survival in patients with papillary bladder tumors [15] . This is consistent with our study which highlights the potential relationship between SFRP1 and tumorigenesis in bladder cancer.
Many miRNAs have been suggested to suppress cancer by targeting SFRP1. For example, miR-27a has been identified to inhibit SFRP1 expression in glioma [13, 28] . However, no literature has reported the relationship between miR-1-3p and SFRP1. Based on previous studies and our findings, we hypothesized that the over-expression of miR-1-3p induces the expression of SFRP1 and inhibits cancerous signals such as invasion, proliferation, migration and apoptosis. In our study, the overexpression of miR-1-3p in J82 cell lines enhanced the induction of SFRP1 at both the mRNA and protein levels, and such an effect was replicated by the overexpression of SFRP1 in J82 cells. However, when we transfected cells with SFRP1 and the miR-1-3p inhibitors, the protein and mRNA expression levels of SFRP1 and the malignant signals in J82 cells showed nearly no difference compared to those of the control group. This supported our view that the expression of miR-1-3p is associated with SFRP1 in J82 cell lines, and that the expression loss of miR-1-3p and SFRP1 is potentially associated with tumorigenesis. This result has never been reported before. Fang et al. found that the overexpression of miR-582-3p activates the Wnt/β-catenin pathway in lung cancer by decreasing the expression of SFRP1 as well as pivotal negative regulators of the Wnt/β-catenin signaling pathway such as AXIN2 and DKK3 [18] . Therefore, we suspected that SFRP1 has different roles in different signaling pathways.
In summary, our study demonstrated for the first time that miR-1-3p inhibits bladder cancer cells with respect to proliferation, invasion and migration by up-regulating the expression of SFRP1. This provides a new insight into the molecular mechanism by which miR-1-3p plays a positive role in bladder cancer. Furthermore, our findings suggest that the miR-1-3p mimics might be one of the potential therapeutic agents. However, ongoing researches should be carried out to verify the above conclusions.
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